![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 23, 2014 8:20:24 PM
Jafar Mahmoudian
Current position
•
2006 to date, Research Associate, Immunochemistry department, Monoclonal
Antibody Research Center, Avicenna Research Institute.
Advisor: Dr. Mahmoud Jeddi-Tehrani
(E-mail: mahjed@yahoo.com)
Current activity
•
Cancer Immunotherapy
Currently, one of our main interests is trying to acquire specific vaccines for various cancers in collaboration with Karolinska institute. Owing to side-effects traits of famous antibodies like Herceptin antibody; we are going to find alternative ones.
http://www.avicenna.ac.ir/Documents/CV/mahmoudian.pdf
Ok.... digging deeper, we have Advisor: Dr. Mahmoud Jeddi-Tehrani, tied directly into Peregrine KOL Hakan Mellstedt:
If you look at the publications... Hakan Mellstedt is all over the place with Dr Mahmoud Jeddi-Tehrani, and Dr. Jeddi-Tehrani has roots back in Karolinska, home of Hakan Mellstedt
Administration
. Head of diagnostic lab of Iran University of medical science.
. Head of Department of Immunology, Avesina Research Center.
. Head of Monoclonal Antibody Research Center.
. Member of Medical Biotechnology board of Iran.
http://www.avicenna.ac.ir/Documents/CV/tehrani.pdf
Is that enough to clearly show that Peregrine has some form of direct/indirect collaborations, stem cell research/vaccines..etc ?
Well that first profile above: Jafar Mahmoudian
5.Production of Monoclonal Antibody against Human Nestin
Reza Hadavi , Amir Hassan Zarnani , Negah Ahmadvand , Ahmad Reza Mahmoudi ,Ali Ahmad Bayat, Jafar Mahmoudian, Mohammad Reza Sadeghi , Haleh Soltanghoraee , Mohammad Mehdi Akhondi, Majid Tarahomi , Mahmood Jeddi-Tehrani , Hodjattallah Rabbani, Avicenna Journal of Medical Biotechnology, Vol. 2, Issue 2 (2010), 69 - 77
http://www.avicenna.ac.ir/Documents/CV/mahmoudian.pdf
well... it looks like I possibly found the connections to the many "followers" of Peregrine from this region of the world, which was puzzling for a bit, but its interesting how many follow very few Big Pharma... but decide to track Peregrine
Everyone follows and tracks for a reason, even everyone on this board. What a wonderful puzzle we have here... : )
Keep Calm and May the (Jeddi) Force Be With You....
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM